menu search

CLSD / Clearside Biomedical: A Pivotal 2022 Ahead

Clearside Biomedical: A Pivotal 2022 Ahead
XIPERE was officially launched by partner Bausch + Lomb in Q1 2022. CLS-AX cohort 3 has fully enrolled with a fourth cohort to be enrolled Q2 2022 pending safety review of cohort 3. Read More
Posted: Apr 13 2022, 06:19
Author Name: Seeking Alpha
Views: 1115100

CLSD News  

3 Cheap Stocks to Buy Under $1 in October 2023

By InvestorPlace
October 26, 2023

3 Cheap Stocks to Buy Under $1 in October 2023

For the extreme gambler who has done homework regarding risk and rewards, few thrills excite as much as cheap stocks to buy under $1. By logical deduc more_horizontal

Clearside Biomedical to Participate in Panel Discussion at the Cantor Global Healthcare Conference

By GlobeNewsWire
September 19, 2023

Clearside Biomedical to Participate in Panel Discussion at the Cantor Global Healthcare Conference

ALPHARETTA, Ga., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delive more_horizontal

Clearside Biomedical to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Monday, August 14, 2023

By GlobeNewsWire
August 1, 2023

Clearside Biomedical to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Monday, August 14, 2023

ALPHARETTA, Ga., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the deliver more_horizontal

Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates

By Zacks Investment Research
May 11, 2023

Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates

Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compa more_horizontal

Clearside Biomedical to Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023

By GlobeNewsWire
May 2, 2023

Clearside Biomedical to Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023

ALPHARETTA, Ga., May 02, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery more_horizontal

Clearside Biomedical, Inc. (CLSD) Q4 2022 Earnings Call Transcript

By Seeking Alpha
March 9, 2023

Clearside Biomedical, Inc. (CLSD) Q4 2022 Earnings Call Transcript

Clearside Biomedical, Inc. (NASDAQ:CLSD ) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ET Company Participants Jenny Kobin - Investor Relati more_horizontal

Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates

By Zacks Investment Research
March 9, 2023

Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -23.08% and 111.54%, respectively, for the quarter ended December 2022. more_horizontal

Clearside Biomedical, Inc. (CLSD) Q3 2022 Earnings Call Transcript

By Seeking Alpha
November 9, 2022

Clearside Biomedical, Inc. (CLSD) Q3 2022 Earnings Call Transcript

Clearside Biomedical, Inc. (NASDAQ:CLSD ) Q3 2022 Earnings Call Transcript November 9, 2022 8:30 AM ET Company Representatives George Lasezkay - Chief more_horizontal


Search within

Pages Search Results: